Do you want to read an article? Please log in or register.
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis
Clin Gastroenterol Hepatol.
Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-Khac E, Meynier J, Fumery M
doi: 10.1016/j.cgh.2020.06.071.
Inflammatory Bowel Disease
Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study
Aliment Pharmacol Ther.
Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN
doi: 10.1111/apt.15177.
COMMENTED
Gastrointestinal DiseasesInflammatory Bowel Disease
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
Clin Gastroenterol Hepatol.
Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN
doi: 10.1016/j.cgh.2020.07.012.
Inflammatory Bowel Disease
High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease
Inflamm Bowel Dis.
Barnes EL, Long MD, Kappelman MD, Martin CF, Sandler RS
doi: 10.1093/ibd/izy378.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
Inflammatory Bowel Disease
Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases
J Crohns Colitis.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F
doi: 10.1093/ecco-jcc/jjaa035.
Inflammatory Bowel Disease
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
Inflamm Bowel Dis.
Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV Jr
doi: 10.1093/ibd/izx076.
Inflammatory Bowel Disease
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study
doi: 10.1093/ecco-jcc/jjy183.
Inflammatory Bowel Disease
Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients
doi: 10.1093/ibd/izy358.